AUS
NZ
UK
CA
USA
IND
Highlights
Pfizer's upcoming quarterly financial report is under scrutiny as activist hedge fund Starboard Value intensifies calls for accountability and results.
Analysts seek evidence of improved profitability and revenue growth, particularly from cancer drugs acquired during recent acquisitions.
The company faces challenges from declining COVID-19 revenue and setbacks in key drug developments, prompting calls for a strategic refocus.
Pfizer's (NYSE:PEE) quarterly financial report, scheduled for release on Tuesday, arrives at a pivotal moment for the pharmaceutical giant and its CEO, Albert Bourla. The scrutiny comes as activist hedge fund Starboard Value increases pressure on the company to showcase tangible results from its turnaround initiatives.
Analysts and stakeholders are eager to see improvements in profitability, especially following significant cost-cutting measures implemented over the past year. There is particular interest in revenue growth from cancer treatments acquired during Pfizer's acquisition spree between 2021 and 2023. Experts believe that enhancing sales will lead to a more robust balance sheet, thereby safeguarding the company's dividend, which currently offers a yield of nearly 6%. This yield is notably higher than that of many other major pharmaceutical firms, providing a rationale for some to retain their shares despite a decline in revenue.
The decline in demand for Pfizer's COVID-19 vaccine and treatment has led to a noticeable drop in its stock price, which is trading at approximately half of its pandemic-era high. Starboard Value has raised concerns about the effectiveness of Pfizer's management, particularly regarding the company's ability to produce profitable new drugs through internal research and development or acquisitions. Starboard CEO Jeff Smith has suggested that leadership changes may be warranted, emphasizing the need for substantial changes rather than complacency.
In addition to declining COVID-19 revenue, Pfizer faces challenges such as disappointing results from a promising obesity drug, a lackluster launch of its respiratory syncytial virus (RSV) vaccine, and the withdrawal of its sickle cell disease treatment Oxbryta due to adverse events in clinical trials. Analysts like Jeff Jonas from Gabelli Funds advocate for Pfizer to streamline its focus to three or four core therapeutic areas, emphasizing recent successes in oncology and vaccines as potential focal points for future growth.
